Negative Press Doesn't Change UBS View on Horizon Pharma (HZNP)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/4/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Express Scripts (ESRX) Says Horizon Pharma (HZNP) Represented 40% of Linden Claims - Bloomberg, Citing Spokesperson
November 11, 2015 3:19 PM ESTExpress Scripts (NASDAQ: ESRX) says Horizon Pharma (NASDAQ: HZNP) represented 40 percent of Linden claims, according to Bloomberg, citing a company spokesperson.
... MoreHorizon Pharma (HZNP) Issues Commentary on Express Scripts' (ESRX) Business Practices
November 11, 2015 12:12 PM EST(NOTE - The following follows an earlier statement made by Horizon.)
Horizon Pharma plc (Nasdaq: HZNP) commented on Express Scripts' (Nasdaq: ESRX) business practices.
"Our philosophy of ensuring that patients get the medicine their doctors prescribe is threatening Express Scripts' profiteering and exposing what we believe is a lack of care for... More
Linden Disruption Expected to Have 'Minimal Impact' on Horizon Pharma (HZNP) - Mizuho
November 11, 2015 11:57 AM ESTMizuho Securities analyst Irina Koffler reiterated a Buy rating and $34 price target on Horizon Pharma (NASDAQ: HZNP), saying they expect minimal impact from Linden disruption.
Koffler commented, "We spoke with management and learned that Linden processes ~150-200 prescriptions for Duexis, Vimovo, Pennsaid, and... More
